Alexion Pharmaceuticals, Inc. (ALXN) Earns Overweight Rating from Barclays PLC

Barclays PLC reissued their overweight rating on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a research report report published on Wednesday, May 24th. They currently have a $155.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages have also recently commented on ALXN. Instinet assumed coverage on Alexion Pharmaceuticals in a research report on Wednesday, March 1st. They issued a buy rating and a $148.00 price target for the company. Nomura assumed coverage on Alexion Pharmaceuticals in a research report on Wednesday, March 1st. They issued a buy rating for the company. Cowen and Company restated a buy rating on shares of Alexion Pharmaceuticals in a research report on Thursday, February 16th. Credit Suisse Group restated a buy rating and issued a $160.00 price target on shares of Alexion Pharmaceuticals in a research report on Friday, February 17th. Finally, Royal Bank of Canada reduced their price target on Alexion Pharmaceuticals from $187.00 to $177.00 and set an outperform rating for the company in a research report on Friday, February 17th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Alexion Pharmaceuticals has a consensus rating of Buy and a consensus target price of $161.38.

Alexion Pharmaceuticals (ALXN) traded down 3.39% on Wednesday, reaching $113.98. The company’s stock had a trading volume of 4,622,346 shares. The stock has a 50-day moving average of $113.46 and a 200-day moving average of $122.45. The stock has a market cap of $25.59 billion, a P/E ratio of 54.30 and a beta of 1.45. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $145.41. Alexion Pharmaceuticals also was the target of unusually large options trading on Wednesday. Stock investors bought 1,630 call options on the company. This represents an increase of approximately 549% compared to the typical volume of 251 call options.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.33. The business had revenue of $870 million during the quarter, compared to analysts’ expectations of $826.63 million. Alexion Pharmaceuticals had a return on equity of 11.72% and a net margin of 14.52%. The business’s quarterly revenue was up 24.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.11 earnings per share. On average, analysts predict that Alexion Pharmaceuticals will post $5.31 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.themarketsdaily.com/2017/06/16/alexion-pharmaceuticals-inc-alxn-given-overweight-rating-at-barclays-plc-updated-updated.html.

In related news, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of the stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average cost of $116.32 per share, with a total value of $156,910,445.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.35% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the company. Guardian Life Insurance Co. of America raised its stake in shares of Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Alexion Pharmaceuticals by 0.4% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,855 shares of the biopharmaceutical company’s stock worth $1,573,000 after buying an additional 47 shares in the last quarter. Grandfield & Dodd LLC raised its stake in shares of Alexion Pharmaceuticals by 1.5% in the first quarter. Grandfield & Dodd LLC now owns 3,270 shares of the biopharmaceutical company’s stock worth $396,000 after buying an additional 47 shares in the last quarter. Cleararc Capital Inc. raised its stake in shares of Alexion Pharmaceuticals by 1.0% in the first quarter. Cleararc Capital Inc. now owns 5,495 shares of the biopharmaceutical company’s stock worth $666,000 after buying an additional 53 shares in the last quarter. Finally, Cim Investment Mangement Inc. raised its stake in shares of Alexion Pharmaceuticals by 1.8% in the fourth quarter. Cim Investment Mangement Inc. now owns 5,433 shares of the biopharmaceutical company’s stock worth $665,000 after buying an additional 94 shares in the last quarter. 94.38% of the stock is owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply